Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.
Other data details announced by Active Biotech show that on the secondary endpoint which measured change in brain volume compared to baseline was positive . Other encouraging results were seen on the secondary endpoint of time to first relapse and the exploratory endpoint of annualized relapse rate, the company said.
“We have learned a great deal from the CONCERTO trial and we will continue our analysis of the data,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “Although we are disappointed by not meeting the primary endpoint, we did see positive results on a number of secondary and exploratory endpoints which fuels our belief in the potential of laquinimod as a possible treatment for neurodegenerative diseases. While we have no current plans to further pursue laquinimod in RRMS, we are continuing to study it in two other trials.”